-- 周四早盘，美元兑主要贸易伙伴走强，市场关注即将公布的每周初请失业金人数数据和芝加哥联邦储备银行3月份全国经济活动指数（均于美东时间上午8:30公布）。 标普全球4月份制造业和服务业状况初值将于美东时间上午9:45公布，随后是美东时间上午10:30公布的每周天然气库存数据，以及美东时间上午11:00公布的堪萨斯城联储4月份制造业指数。 周四外汇市场动态简报： 欧元兑美元汇率从周三美股收盘时的1.1706跌至1.1681，周三早盘同一时间点的汇率为1.1752。根据周四早些时候公布的数据，欧元区4月份制造业采购经理人指数（PMI）上升，但服务业PMI下降。欧洲央行下一次会议定于4月30日举行。 英镑/美元汇率从周三美国收盘时的1.3504和周三早盘的1.3516跌至1.3488。根据周四早些时候公布的数据，英国4月份制造业和服务业采购经理人指数（PMI）均有所增长，而英国3月份汽车注册量在经历了上月的下滑后出现反弹。英国央行下一次会议定于4月30日举行。 美元/日元汇率从周三美国收盘时的159.5489和周三早盘的159.2295升至159.7290。日本4月份制造业PMI有所增长，而服务业PMI有所下降，但仍高于盈亏平衡点。日本央行下一次会议定于4月27日至28日举行。 美元/加元汇率从周三美国收盘时的1.3668和周三早盘的1.3655升至1.3671。加拿大3月份工业产品和原材料价格以及房屋价格将于美国东部时间上午8:30公布。加拿大央行下次会议定于4月29日举行。
Related Articles
Treasury
Scotiabank Previews This Week's February and Preliminary March GDP for Canada
Canada reports gross domestic product for February and the preliminary estimate for March on Thursday, said Scotiabank.February was initially guided by Statistics Canada to have been tracking a 0.2% month-over-month gain last month. Updated estimates are still in the same ballpark, but investors also get important details on sector drivers, noted the bank.More meaningful may be the flash guidance, with no details, for March GDP, for which there is very little information so far, but a small gain is "feasible," stated Scotiabank.The outcome will further inform Q1 GDP growth tracking on a production/income basis using monthly GDP. It's feasible that growth is tracking close to the Bank of Canada's 1.8% January Monetary Policy Report estimate, but that's on an expenditure basis. The massive over 4% inventory drag on Q4 GDP could reverse as an added upside, pointed out the bank.One key is that consumer spending on goods is tracking a strong rebound in Q1 based on retail sales volumes. It's untrue that the economy isn't exhibiting rate sensitivity, a view that is disproportionately driven by a false understanding of what's keeping condo markets weak in Toronto and Vancouver, added Scotiabank.
$$CXY
Australia
Vicor Insider Sold Shares Worth $2,079,226, According to a Recent SEC Filing
Alvaro Doyle, Vice President and Chief Information Officer, on April 23, 2026, sold 8,000 shares in Vicor (VICR) for $2,079,226. Following the Form 4 filing with the SEC, Doyle has control over a total of 42 common shares of the company, with 42 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/751978/000182673026000002/xslF345X05/primary_doc.xmlPrice: $265.29, Change: $-8.24, Percent Change: -3.01%
$VICR
Australia
BioMarin Seen Building Broader Rare-Disease Platform After Amicus Deal, Morgan Stanley Says
BioMarin Pharmaceutical (BMRN) is emerging as a broader rare-disease platform as its acquisition of Amicus Therapeutics (FOLD) adds two approved medicines and reduces reliance on Voxzogo, Morgan Stanley said Monday in a report.The Amicus deal reshapes BioMarin's outlook by adding Galafold and Pombiliti with Opfolda, products that fit the company's global commercial network, the report said. The therapies are expected to generate more than $1.3 billion in revenue by 2030, Morgan Stanley said.The acquisition is projected to accelerate revenue growth immediately after closing and to be accretive to non-GAAP earnings within 12 months, with "substantial accretion" beginning in 2027, the report said. BioMarin closed its $4.8 billion purchase of Amicus on Monday.Morgan Stanley resumed coverage on BioMarin stock with an overweight rating and a $120 price target.Price: $54.08, Change: $+0.90, Percent Change: +1.68%
$BMRN$FOLD